COVID-19 infection can raise PSA levels, sometimes substantially. A prospective study of men with benign prostatic conditions found that average PSA roughly tripled during active infection, jumping from about 1.6 ng/mL before illness to about 4.3 ng/mL during it, then settling back down after recovery. The effect is real enough that researchers have recommended waiting at least a month after clearing a COVID infection before drawing blood for PSA screening. But the picture is not perfectly simple, and the size of the bump varies across studies, patient populations, and disease severity.
How SARS-CoV-2 Could Reach the Prostate
The virus that causes COVID-19 enters human cells by latching onto a surface protein called ACE2, with help from a second protein called TMPRSS2. Both of these proteins show up in prostate tissue. Single-cell analysis of normal human prostate tissue identified cells co-expressing both proteins across several cell types, with the highest proportions found in club cells (about 0.6%) and hillock cells (about 0.4%), which bear a strong resemblance to similar cells in the lungs.1PubMed Central. Expression of ACE2, the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells A separate analysis of gene expression across urological tissues found that ACE2 levels in the prostate are comparable to those in the lungs.2PubMed Central. Angiotensin-converting enzyme 2 gene expression in human male urological tissues: implications for pathogenesis and virus transmission pathways
That said, having the right receptors does not mean the virus routinely infects the prostate in a clinically meaningful way. When researchers tested prostatic fluid from COVID-19 patients, all 89 samples came back negative for the virus.3F&S Reviews. COVID-19 may affect male fertility but is not sexually transmitted: a systematic review So while the prostate has the biological hardware that could theoretically allow viral entry, direct prostatic infection appears to be uncommon. The more likely explanation for PSA changes during COVID-19 involves inflammation rather than the virus literally setting up shop in prostate tissue.
What the Studies Found
The strongest direct evidence comes from a prospective cohort study of 91 men with benign prostatic hyperplasia who had PSA measurements taken before, during, and after COVID-19. Their average PSA rose from about 1.6 ng/mL before infection to roughly 4.3 ng/mL during active disease, then dropped back to about 2.1 ng/mL after recovery. The difference between the active-infection reading and both the pre-infection and post-infection readings was statistically significant.4PubMed Central. Variation of Serum PSA Levels in COVID-19 Infected Male Patients with Benign Prostatic Hyperplasia (BPH): A Prospective Cohort Study For context, that mid-infection average of 4.3 is right at the threshold where many clinicians start recommending further prostate investigation, even though these men’s baseline levels were well below it.
A much larger retrospective study looking at a broader population found a more modest but still real effect. Among men who had COVID-19, about 7.3% experienced a PSA increase of 1 ng/mL or more, compared to 6% in the control group. The relative risk for that level of PSA bump was about 1.22. When the threshold was set lower, at a rise of 0.35 ng/mL or more, roughly 20% of COVID-positive men hit it versus about 19% of controls.5PubMed Central. Prostate-specific antigen level association with COVID-19 infection and vaccination These numbers tell a somewhat different story than the cohort study: yes, COVID increases the odds of a PSA rise, but for many men the bump is small.
Interestingly, not every study points in the same direction. One Turkish investigation actually found that total PSA and free PSA were lower in men with COVID-19 compared to controls.6Journal of Bursa Faculty of Medicine. Does Covid-19 affect lower urinary tract symptoms (LUTS) of male patients? The reasons for the discrepancy are not entirely clear, though differences in disease severity, timing of blood draws relative to the infection, and patient demographics could all play a role. The weight of the evidence tilts toward COVID raising PSA for most men, but the effect is not universal or uniform.
Why Inflammation Pushes PSA Into the Bloodstream
PSA is produced by the prostate gland and normally stays mostly confined within the glandular tissue. It reaches the bloodstream in small, measurable amounts, which is what a PSA test picks up. When the prostate or surrounding tissue becomes inflamed, the barriers that normally keep PSA inside the gland get disrupted. Inflammation damages the epithelial and basement membrane layers, essentially opening gaps that allow PSA to leak into the circulation in larger quantities.7Urogenital Tract Infection. Beyond the Number: Interpreting Prostate-Specific Antigen Elevation in the Context of Prostate Inflammation – Section: PROSTATITIS RAISES PSA – MAGNITUDE, DURATION, MECHANISMS
This is the same reason bacterial prostatitis, urinary tract infections, and even vigorous physical activity like cycling can temporarily raise PSA. The prostate does not have to be directly infected by a pathogen for PSA to rise. A severe systemic inflammatory response, like the kind COVID-19 is known to trigger, can disrupt those barriers from the outside. COVID-19 is particularly notable for its ability to provoke widespread inflammation affecting multiple organ systems, so a spillover effect on prostate tissue is biologically plausible even without the virus infecting prostate cells directly.
While the possibility of SARS-CoV-2 causing actual prostatitis cannot be ruled out, the evidence linking the two is limited.8PubMed Central. COVID-19 and Prostatitis: A Review of Current Evidence In most cases, the PSA bump during COVID likely reflects the body’s inflammatory storm rather than a targeted infection of the prostate itself.
COVID Is Not Unique Here
One of the most useful things to understand about COVID-related PSA changes is that other infections can do the same thing. A study of young military members found that infectious mononucleosis was associated with larger PSA rises than seen in controls. About a fifth of men with mono experienced a PSA increase of 20% or more, compared to under 9% of healthy controls. Men with other non-genitourinary infections also showed elevated PSA readings compared to controls.9PubMed. Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection The researchers suggested that PSA rises during systemic infections, not just during infections of the prostate or urinary tract, which matters for how doctors interpret results in older men who get screened regularly.
Follow-up research on the same military cohort examined C-reactive protein, a general marker of inflammation in the blood, alongside PSA. The patterns suggested that systemic inflammation from infections was driving the PSA changes, reinforcing the idea that the prostate does not need to be the site of infection for PSA to go up.10PubMed Central. Insight into infection-mediated prostate damage: Contrasting patterns of C-reactive protein and prostate-specific antigen levels during infection Even shingles reactivation has been documented to cause spurious PSA elevation in a prostate cancer patient, prompting warnings against unnecessary biopsies or treatment changes based on infection-period lab values.11PubMed Central. Spurious elevation of Prostate-specific antigen associated with shingles in a prostate cancer patient undergoing active surveillance
An earlier guidance review noted that before COVID-specific data emerged, the literature on systemic viral infections and PSA was thin. A study of Epstein-Barr virus infections found that only about 5.9% of infected patients had a PSA rise of more than 0.50 ng/mL, while nonspecific systemic viral infections were linked to rises greater than 0.20 ng/mL more often than in controls. The overall conclusion was that systemic viral infections may produce a small PSA bump, particularly relevant for men on active surveillance or watchful waiting programs.12European Urology Open Science. Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists – Section: 3.4.2. Prostate-specific antigen
The takeaway is that COVID-19 fits into a broader pattern. PSA is sensitive to any inflammatory insult, and a serious viral illness like COVID-19, with its tendency to provoke intense systemic inflammation, is exactly the kind of event that would push PSA upward temporarily.
Practical Advice for PSA Screening After COVID
If you had COVID-19 recently and are due for a PSA test, the most practical advice is to wait. Researchers studying PSA changes in COVID patients have recommended that if a PSA measurement falls in the “gray zone” (usually defined as roughly 4 to 10 ng/mL), the test should be repeated at least one month after recovering from the infection.13CirugÃa y Cirujanos. Changes in prostate specific antigen value in patients with COVID-19 This matches general urology practice, where clinicians have long recommended against drawing PSA during any acute illness, urinary infection, or within days of procedures that manipulate the prostate.
The prospective cohort data showing PSA dropping back toward baseline after recovery is reassuring on this point.4PubMed Central. Variation of Serum PSA Levels in COVID-19 Infected Male Patients with Benign Prostatic Hyperplasia (BPH): A Prospective Cohort Study For most men, the elevation appears to be transient. But if you are on active surveillance for prostate cancer and your PSA ticks up after a bout of COVID, that context is worth sharing with your urologist before making any decisions about biopsies or treatment changes. An infection-related PSA rise does not mean your cancer is progressing.
The one-month waiting period is a reasonable minimum. Some men, particularly those who had severe infections or prolonged symptoms, may need longer for their inflammatory markers to fully settle. There is no rigid rule here, but the principle is straightforward: give your body time to return to its baseline state before treating a PSA reading as reliable.
COVID-19 and Lower Urinary Tract Symptoms
Beyond PSA changes, COVID-19 can affect the lower urinary tract more broadly. Multiple studies have documented new-onset urinary symptoms in COVID-positive patients, particularly increased urinary frequency, urgency, and nighttime urination. One study found that these storage-type symptoms could appear even in people with no prior urinary problems, and that the severity of urinary symptoms tracked with the severity of the COVID-19 infection itself.14PubMed Central. The Effect of Covid-19 Severity on Lower Urinary Tract Symptoms Manifestations Another study specifically examined de novo lower urinary tract symptoms, meaning symptoms that were entirely new, and found that their severity influenced how long patients stayed in the hospital.15PubMed Central. De Novo Lower Urinary Tract Symptoms in COVID-19 Patients
The phenomenon is not limited to adults. A study of children with COVID-19 documented sudden-onset urinary frequency and urgency that lasted for weeks before gradually resolving. Standardized symptom scores jumped dramatically during the illness compared to pre-infection baselines.16PubMed Central. COVID-19 associated lower urinary tract symptoms in children This is worth knowing because urinary symptoms during or after COVID can be alarming, and men in particular might worry that new urgency or frequency points to a prostate problem. In many cases, the symptoms are a direct consequence of the viral illness and resolve on their own.
Effects on Male Reproductive Health Beyond PSA
COVID-19’s influence on the male urogenital system extends beyond the prostate. Autopsy studies and animal models have documented damage to testicular tissue, including disruption of the barrier that normally protects the testes from immune attack.17PubMed Central. Testicular pathological alterations associated with SARS-CoV-2 infection A systematic review and meta-analysis found an association between SARS-CoV-2 infection and primary testicular damage, manifesting as altered hormone production and worsened sperm quality.18PubMed Central. Impact of COVID-19 on testicular function: a systematic review and meta-analysis
For men who are trying to conceive or concerned about fertility, this is relevant context. The testicular effects appear to involve both direct viral action (the testes also express ACE2) and the broader inflammatory response. Most of the documented changes have been observed in the acute phase of illness, and the long-term reproductive consequences are still being studied. As with PSA levels, the general advice is that acute-phase findings do not necessarily predict permanent damage, but men with ongoing concerns should discuss them with a urologist or reproductive specialist.
When a PSA Test Is Drawn During Treatment for COVID
Some men end up having blood work done while they are actively hospitalized for COVID-19, and PSA results from that window deserve extra skepticism. Severe COVID is often treated with corticosteroids like dexamethasone, which have their own complex effects on inflammation and immune function.19PubMed Central. The Effect of Dexamethasone Treatment on COVID-19 Prognosis in Cancer Patients Corticosteroids dampen systemic inflammation, which could theoretically blunt some of the inflammation-driven PSA rise. But they do not eliminate it, and the timing of steroid administration relative to the blood draw makes the PSA reading even harder to interpret.
Hospitalized patients may also have Foley catheters, which are known to irritate the prostate and independently elevate PSA. The combination of acute viral illness, systemic inflammation, medication effects, and potential catheter use makes any PSA value drawn during a COVID hospitalization essentially uninterpretable for prostate cancer screening purposes. If a PSA result appears in your hospital discharge paperwork, treat it as a snapshot of a chaotic moment in your body’s physiology rather than a meaningful data point about your prostate health.
The broader lesson is one that urologists have been emphasizing for years, and COVID has only reinforced: PSA is a useful screening tool, but it is exquisitely sensitive to conditions that have nothing to do with cancer. Infections, inflammation, physical activity, and medical procedures can all nudge it upward. COVID-19 happens to combine several of those triggers at once, which is why the inflation can be so dramatic in some patients. If your PSA comes back higher than expected after a recent COVID infection, the most sensible first step is simply to wait and retest.